Document is current
Any future updates will be listed below
-
Authors
Holt, Brandon Alexander https://orcid.org/0000-0002-8204-4984
Tuttle, McKenzie
Xu, Yilin
Su, Melanie
Røise, Joachim J https://orcid.org/0000-0002-1794-7570
Wang, Xioajian https://orcid.org/0000-0002-1502-8781
Murthy, Niren
Kwong, Gabriel A https://orcid.org/0000-0002-6255-6755
-
Funding
Funding for this research was provided by:
HHS|NIH|National Center for Advancing Translational Sciences (DP2HD091793)
HHS|NIH|NCI|Division of Cancer Epidemiology and Genetics, National Cancer Institute (GR10003709)
National Science Foundation (DGE‐1650044)
HHS|NIH|National Institute of Biomedical Imaging and Bioengineering (5T32EB006343)
- License Information
-
More Information
Article History
Received: 9 June 2021
Revised: 15 December 2021
Accepted: 17 December 2021
First Online: 10 January 2022
Disclosure statement and competing interests
: KGA is co‐founder of Glympse Bio, and consults for Glympse Bio and Satellite Bio. This study could affect his personal financial status. The terms of this arrangement have been reviewed and approved by Georgia Tech in accordance with its conflict of interest policies. HBA and KGA are listed as inventors on a patent application pertaining to the results of the paper. The title of the patent is “Self‐titrating, bacterial protease‐activated prodrug”. The patent applicant is the Georgia Tech Research Corporation and the names of the inventors are Brandon Holt and Gabriel Kwong. The patent is currently pending and the application numbers are 62/733,347 (U.S.) and WO 2020061244A2 (International). The AMP prodrug and the BAH are covered in the patent.
